Cibc World Markets Corp Has $2.64 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cibc World Markets Corp increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 16.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,676 shares of the medical equipment provider’s stock after buying an additional 5,075 shares during the quarter. Cibc World Markets Corp’s holdings in Hologic were worth $2,644,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Benson Investment Management Company Inc. acquired a new stake in Hologic during the fourth quarter worth about $4,832,000. Principal Financial Group Inc. grew its position in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after buying an additional 1,606 shares in the last quarter. Clean Yield Group lifted its stake in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares during the period. Janus Henderson Group PLC lifted its stake in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after purchasing an additional 800 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Hologic during the third quarter worth about $2,350,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

HOLX stock opened at $61.01 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a 50 day moving average price of $66.26 and a 200 day moving average price of $74.19. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The stock has a market capitalization of $13.69 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HOLX. Stephens restated an “overweight” rating and set a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Wolfe Research began coverage on shares of Hologic in a research note on Friday, December 13th. They set a “peer perform” rating for the company. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research note on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.